Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 13, 2026

Stocks Fall on Weakness in Software and Credit Card Companies

View original at nasdaq.com
Stocks Fall on Weakness in Software and Credit Card Companies The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.19%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.80%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.18%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Credit-card lenders would be in violation of the law if they don't cap interest rates at 10% for one year

    80% confidence

  • The vaccine schedule is not based on scientific evidence and will harm the public

    80% confidence

  • The US economy is pretty robust and he expects above-potential growth

    80% confidence

  • Option Care Health's forecast for 2026 EBITDA growth of +2% to +7% are better than expected

    80% confidence

  • Justice Department was threatening a criminal indictment tied to his June testimony on Fed headquarters renovations

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%

    80% confidence

  • It is unnecessary and unadvisable for the Fed to take an accommodative stance

    80% confidence

  • S&P earnings growth is expected to climb by +8.4% in Q4

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Stocks Fall on Weakness in Software and Credit Card Companies — Source | Via News | ViaNews EU